Home / KEEP BUT DO NOT DISPLAY / Alerts / Newsflash: The FDA has accepted Bristol-Myers Squibb’s New Drug Application for dapagliflozin

Newsflash: The FDA has accepted Bristol-Myers Squibb’s New Drug Application for dapagliflozin

Mar 9, 2011
1,395 views

The FDA has accepted Bristol-Myers Squibb’s New Drug Application for its first in class drug dapagliflozin, an investigational selective sodium-glucose cotransporter-2 inhibitor (SGLT2), first in class compound for the treatment of adults with Type 2 diabetes.